Professor Santin at Yale University (New Haven, USA) and his group have conducted preclinical research into the anti-tumor activity of SYD985 in Uterine Serous Carcinoma (USC).
This is a disease with a high unmet medical need as no HER2-targeting therapy is available. Using in vitro testing and in vivo mouse models, Professor Santin and his co-workers indicate that SYD985 has remarkable anti-tumor activity in a subset of patients with strong (IHC3+) but also with low to moderate (IHC1+/2+) HER2 expression.
In comparative preclinical experiments, SYD985 was significantly more potent than T-DM1 (Kadcyla®, a trastuzumab-tubulin-binder containing ADC from Roche/Genentech). In a scientific article published in Molecular Cancer Therapeutics, Professor Santin's group advocates performing clinical studies with SYD985 as a potential next-line treatment for USC patients whose disease has become resistant to standard chemotherapy.
Synthon has included a cohort of these endometrial (uterine) cancer patients in part B of the ongoing Phase I clinical trial.